BD Statement on BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 Assay

FRANKLIN LAKES, N.J. (Sept. 15, 2020)– BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement:

BD is aware that a small number of nursing homes in the U.S. are reporting multiple false positive results from tests for SARS-CoV-2 on the BD Veritor™ Plus system. These reports do not reflect the results of BD clinical studies conducted using the BD Veritor™ Plus system, where the sampling data showed 98% to 100% specificity (negative percent agreement). Following our standard quality management system processes, upon learning of these reports, BD immediately contacted the sites, and we are actively investigating the situation to obtain additional details. Our quality investigation is ongoing, however, as of Sept. 15, there have been no issues found with the BD Veritor™ Plus instruments or tests.

BD takes its responsibility very seriously under our agreement with the U.S. Department of Health and Human Services (HHS) to provide more than 11,000 nursing homes with high-quality and reliable tests to support their efforts to protect residents and staff from COVID-19. BD is providing a robust array of training tools to support the use of BD Veritor™ Plus system and to ensure successful implementation of the nursing home initiative.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.

Contacts:

Troy Kirkpatrick
BD Public Relations
858.617.2361
troy.kirkpatrick@bd.com

Kristen Stewart
BD Investor Relations
201.847.5378
kristen.stewart@bd.com

Additional assets available online: Photos (1)

https://news.bd.com/2020-09-15-BD-Veritor-TM-Plus-System-for-Rapid-Detection-of-SARS-CoV-2-Assay